BioAlliance Pharma extends and strengthens the protection of AMEP®

with the grant of two patents in the US

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan oncology products and to supportive care products, announces two key achievements in the development of its biotherapy AMEP® with the decision of granting two patents by the USPTO (United States Patent and Trademark Office).
AMEP® is a protein targeting specific receptors expressed on melanoma cells and involved in both tumor growth and angiogenesis (inhibition of tumor vascularization necessary for its growth). As the protein cannot be directly administered, the Company has developed a technology aiming at administering the specific gene (the AMEP® biotherapy) which, once inside the cell, will enable synthesis of the active AMEP® protein.
After Asia and Europe, BioAlliance Pharma has obtained the US patent protecting the metastatic melanoma treatment by the AMEP® biotherapy. This patent provides a protection until 2022. Moreover, the USPTO has recently given its allowance to deliver another patent on this same product to BioAlliance Pharma, covering the specific method of administration of the gene coding for AMEP® protein until 2026.
” We are particularly proud of these American grants as patents based on the use of genes are particularly difficult to obtain from the USTPO. These decisions reinforce and extend the protection of our product and confirm the innovation brought by our AMEP® biotherapy”, declares Aude Michel, Vice President Licensing and Legal Affairs, and European Patent Attorney of BioAlliance Pharma.
BioAlliance Pharma is pursuing the development of AMEP® with a second European Phase I/II trial via intramuscular administration. It aims at evaluating the safety and efficacy profile via systemic route in patients with metastatic melanoma.
« Intellectual property is a key asset of the Company. BioAlliance Pharma’s portfolio reflects the Company’s strategy and its capacity of innovation; the portfolio today consists of 22 families of published patents, including 289 patents and patent applications related to our products and technologies. The patents granted by the American authorities on the AMEP® biotherapy reinforce the value of this promising asset by ensuring a protection on this key market, and ensure a protection already well established”, added Judith Greciet, CEO of BioAlliance Pharma.

120712EN_Amep Brevet